GlassScriptPhysician profile
Charles J Wray
NPI 1285662148
$19,729.73
in general payments reported to CMS, 2019-2025
44 companies · $2,848 in 2025
The $2,848 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,816 · 2020: $1,805 · 2021: $1,597 · 2022: $1,946 · 2023: $2,431 · 2024: $6,287 · 2025: $2,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,488 · Education: $2,742 · Travel and Lodging: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,487.91 |
| Education | $2,742.35 |
| Travel and Lodging | $1,335.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,852.37 | 2024 | |
| Glaxosmithkline, LLC. | $2,806.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,203.79 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Jazz Pharmaceuticals INC. | $1,922.41 | 2019-2025 | |
| Harmony Biosciences LLC | $1,675.00 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $1,318.85 | 2019-2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $852.36 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $793.90 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $656.93 | 2019-2024 | Uptravi, Opsumit |
| Genzyme Corporation | $517.97 | 2022-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $433.18 | 2023-2025 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $339.09 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $262.98 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $252.39 | 2019-2024 | Tyvaso |
| Baxter Healthcare | $168.32 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Tisseel |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $166.36 | 2019-2022 | |
| Axsome Therapeutics, INC. | $157.70 | 2022-2025 | Sunosi |
| Pulmonx Corporation | $157.61 | 2019-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Gilead Sciences, INC. | $143.93 | 2021-2023 | Veklury |
| Verona Pharma, INC. | $109.30 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $104.07 | 2024-2025 | Acthar |
| Zoll Respicardia, INC. | $103.56 | 2023-2024 | Remede System |
| Mylan Specialty L.P. | $72.24 | 2019-2023 | Yupelri |
| Genentech USA, INC. | $71.37 | 2019-2020 | |
| Ethicon INC. | $56.04 | 2024 | Monarch Platform |
| Endogastric Solutions, INC | $54.72 | 2022 | |
| Ani Pharmaceuticals, INC. | $54.36 | 2024 | Purified Cortrophin Gel |
| Pfizer INC. | $53.63 | 2022-2024 | |
| Advanced Respiratory, INC | $51.53 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $50.02 | 2022-2024 | |
| Vifor Pharma, INC. | $32.54 | 2025 | Zemaira |
| Noctrix Health, INC. | $30.13 | 2025 | Nidra |
| Sunovion Pharmaceuticals INC. | $28.31 | 2019 | |
| Ambu INC. | $22.76 | 2022 | |
| Mallinckrodt Enterprises LLC | $18.39 | 2019 | |
| Electromed, INC. | $17.73 | 2024 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $17.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.32 | 2021 | |
| Vapotherm INC | $15.31 | 2022 | |
| Boston Scientific Corporation | $15.24 | 2023 | Exalt Model D |
| Shire North American Group INC | $15.19 | 2019 | |
| Mayne Pharma Commercial LLC | $13.62 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.26 | 2023 | Nuzyra |
| Circassia INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.